What is the NOAEL for 4-Aminobenzoic acid?
4-Aminobenzoic acid has 49 NOAEL studies in the database. The lowest reported value is 0 uL/min/10^6 cells in Human. Source: NTP ICE adme parameters.
NOAEL Data
IARC Group 3
REACH Registered
Cosmetic Ingredient
4-Aminobenzoic acid
Also known as: 1-Amino-4-carboxybenzene, BRN 0471605, Caswell No. 033B, EINECS 205-753-0, EPA Pesticide Chemical Code 233300 (+15 more)
CAS 150-13-0
4-Aminobenzoic acid (CAS 150-13-0) is a chemical substance; key hazard signal: IARC Group 3. Key regulatory status: REACH registered, 5 regulatory/inventory lists, cosmetic ingredient cross-reference; source data from EPA ToxValDB, EPA CPDat, AICIS, SCCS, IARC, ECHA REACH.
SOURCE
NOAEL studies
NOAEL studies
49
SOURCE
Chemical inventory jurisdictions
Regulatory lists
5
SOURCE
EU CLP Annex VI
GHS signal
Not classified
Chemical Identity
CAS, identifiers, formula, and alternate names for the matched substance record.
SOURCE
DSSTox identifiers
25 fields
Name
4-Aminobenzoic acid
CAS Number
150-13-0
Molecular Formula
C7H7NO2
InChI Key
ALYNCZNDIQEVRV-UHFFFAOYSA-N
Monoisotopic Mass
137.047678
Synonyms
1-Amino-4-carboxybenzeneBRN 0471605Caswell No. 033BEINECS 205-753-0EPA Pesticide Chemical Code 233300Super Shade by CoppertoneUNII-TL2TJE8QTX4-AminobenzoateAcido p-aminobenzoicoAcidum paraminobenzoicumAmbenAminobenzoate
IARC Carcinogen Classification
Carcinogenic hazard classification from IARC monograph evaluations.
SOURCE
IARC Monographs on the Identification of Carcinogenic Hazards to Humans
1 records
| Group | Meaning | Evaluated | Volume |
|---|---|---|---|
| Group 3 | Not classifiable | 1987 | 16, Sup 7 |
Functional Uses
Industrial and product-use categories associated with this substance.
SOURCE
EPA CPDat
8 records
UV stabilizerFlavouring and nutrientNo specific technical function
Regulatory Lists
Inventory, screening, and regulatory list matches from public chemical databases.
SOURCE
EPA CPDat
5 records
| List | Keyword | Source |
|---|---|---|
| banned; Europe; Personal care | European Commission | CosIng |
| inert_ingredient; non_food_use; Pesticides | EPA | CPCat |
| Canada; pharmaceutical | DrugBank | DrugBank |
| food_additive; Substances Added to Food (formerly EAFUS) (2/2019) | FDA | United States Food and Drug Administration (FDA) |
| Europe; Personal care | Danish Environmental Protection Agency | Danish EPA |
NOAEL Studies
Toxicology endpoints rendered from public NOAEL study rows.
SOURCE
NOAEL studies
Showing 49 of 49 studies
| Value | Unit | Endpoint | Route | Species | Source |
|---|---|---|---|---|---|
| 0.1 | % | - | oral | rat | Regulatory source |
| 1 | % | - | oral | rat | Regulatory source |
| 108 | - | - | oral | - | Regulatory source |
| >200 | ug/mL | CD86, EC150 | Dermal | - | NTP ICE skin sensitization |
| >1000 | ug/mL | CV75 | Dermal | - | NTP ICE skin sensitization |
| 0 | uL/min/10^6 cells | Clint | - | Human | NTP ICE adme parameters |
| =10.58 | mg/m3 | DNEL systemic | inhalation | Human | ToxValDB GESTIS DNEL |
| 1 | % | Depletion Cys | Dermal | - | NTP ICE skin sensitization |
| 1.4 | % | Depletion Cys | Dermal | - | NTP ICE skin sensitization |
| 3.9 | % | Depletion Cys | Dermal | - | NTP ICE skin sensitization |
| 4.6 | % | Depletion Cys | Dermal | - | NTP ICE skin sensitization |
| 5.9 | % | Depletion Cys | Dermal | - | NTP ICE skin sensitization |
| 10.6 | % | Depletion Cys | Dermal | - | NTP ICE skin sensitization |
| 10.7 | % | Depletion Cys | Dermal | - | NTP ICE skin sensitization |
| 0 | % | Depletion Lys | Dermal | - | NTP ICE skin sensitization |
| 0.1 | % | Depletion Lys | Dermal | - | NTP ICE skin sensitization |
| 0.4 | % | Depletion Lys | Dermal | - | NTP ICE skin sensitization |
| 0.5 | % | Depletion Lys | Dermal | - | NTP ICE skin sensitization |
| 0.6 | % | Depletion Lys | Dermal | - | NTP ICE skin sensitization |
| 0.7 | % | Depletion Lys | Dermal | - | NTP ICE skin sensitization |
| 0.9 | % | Depletion Lys | Dermal | - | NTP ICE skin sensitization |
| 0.35 | % | Depletion Lys + Cys | Dermal | - | NTP ICE skin sensitization |
| 0.45 | % | Depletion Lys + Cys | Dermal | - | NTP ICE skin sensitization |
| 1.05 | % | Depletion Lys + Cys | Dermal | - | NTP ICE skin sensitization |
| 2.3 | % | Depletion Lys + Cys | Dermal | - | NTP ICE skin sensitization |
| 2.35 | % | Depletion Lys + Cys | Dermal | - | NTP ICE skin sensitization |
| 2.4 | % | Depletion Lys + Cys | Dermal | - | NTP ICE skin sensitization |
| 3.2 | % | Depletion Lys + Cys | Dermal | - | NTP ICE skin sensitization |
| 5.55 | % | Depletion Lys + Cys | Dermal | - | NTP ICE skin sensitization |
| 5.6 | % | Depletion Lys + Cys | Dermal | - | NTP ICE skin sensitization |
| >2000 | uM | EC1.5 | Dermal | - | NTP ICE skin sensitization |
| TL2TJE8QTX | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| 0.766 | fraction | Fu | - | Human | NTP ICE adme parameters |
| 3 | IARC group | IARC carcinogenicity classification | - | - | IARC Monographs |
| 3 | unitless | IARC group | - | - | NTP ICE cancer |
| >2400 | uM | IC50 | Dermal | - | NTP ICE skin sensitization |
| 1.107 | ratio | Imax | Dermal | - | NTP ICE skin sensitization |
| 1.21 | ratio | Imax | Dermal | - | NTP ICE skin sensitization |
| 1.23 | ratio | Imax | Dermal | - | NTP ICE skin sensitization |
| 0 | % | Incidence of positive responses | Dermal | Human | NTP ICE skin sensitization |
| 1.552e+4 | ug/cm2 | Induction dose per skin area | Dermal | Human | NTP ICE skin sensitization |
| 0 | unitless | Model Score | - | - | NTP ICE endocrine |
| =0.1 | % | NOAEL | oral | rat | SCCS Opinion |
| =1 | % | NOAEL | oral | rat | SCCS Opinion |
| =100 | mg/kg bw/d | NOAEL | oral | rat | SCCS Opinion |
| =108 | - | NOAEL | oral | - | SCCS Opinion |
| >=1200 | mg/kg bw/day | NOAEL | oral | Rat | ECHA |
| 1 | unitless | Relative reliability score | Dermal | Human | NTP ICE skin sensitization |
| 100 | mg/kg bw/d | repeated dose toxicity | oral | rat | Regulatory source |
Showing 49 of 49 studies
REACH Registration
Registration status from the ECHA REACH registered substances database.
SOURCE
ECHA
1 records
| Status | Name | EC Number | Link |
|---|---|---|---|
| Registered | 4-aminobenzoic acid | 205-753-0 | ECHA overview → |
Australian Status (AICIS)
Australian industrial chemicals inventory status and applicable conditions.
SOURCE
AICIS inventory
1 records
Inventory Status
listed
SCCS Opinions
EU Scientific Committee opinions tied to the matched substance.
SOURCE
SCCS Opinion
2 opinions
| Opinion | Date | Conclusion | Max Conc. | Concerns |
|---|---|---|---|---|
| SCCP/0937/05 | 20 June 2006 | safe | up to 5% | Photocontact allergic reactions reported; skin sensitisation risk; declining use in favour of alternatives; no mutagenic/carcinogenic/teratogenic risk identified; possible thyroid disrupting activity (not confirmed) |
| SCCP/1008/06 | 2006-06-20 | Although 4-aminobenzoic acid is presently permitted and used as a sunscreen, it became apparent in the process of evaluation of the dossier that much of the information did not conform to current standards and guidelines. Before any further evaluation of the use of 4-aminobenzoic acid, both as a UV-filter and for purposes other than a UV filter, the SCCP requires a new dossier in which data to all relevant toxicological endpoints and conform to modern standards and SCCNFP/SCCP guidelines to be submitted before 1 July 2007. | 5% (currently authorised maximum as UV filter; not re-confirmed) | Much of the dossier information did not conform to current standards and guidelines; a new dossier with data to all relevant toxicological endpoints required (deadline 1 July 2007); applicant must specify other intended purposes. Pharmaceutical-grade purity issues noted (specified 98.5%). |
Cosmetic Safety Profile
Same-CAS cosmetic ingredient record for cross-vertical context.
SOURCE
CosIng / Ingredients DB
EU Status
restricted
Max
II/167
Category
UV Filters
Pharmaceutical Data
Same-CAS pharmaceutical records from drug and bioactivity sources.
SOURCE
ChEMBL / DailyMed
AMINOBENZOIC ACID
ChEMBL Phase
-1
Adverse Events
715
Bioactivity
12
Frequently Asked Questions
What regulatory lists include 4-Aminobenzoic acid?
4-Aminobenzoic acid appears on 5 regulatory/inventory lists including banned; Europe; Personal care, inert_ingredient; non_food_use; Pesticides, Canada; pharmaceutical, and 2 more. Source: EPA CPDat.
Is 4-Aminobenzoic acid a carcinogen according to IARC?
4-Aminobenzoic acid is classified by IARC as Group 3 — not classifiable as to its carcinogenicity to humans (evaluated 1987). Source: IARC Monographs on the Identification of Carcinogenic Hazards to Humans.
Is 4-Aminobenzoic acid used in cosmetics?
Yes, 4-Aminobenzoic acid is also indexed as a cosmetic ingredient under the name PABA. View the full cosmetic safety profile on the ingredient page for detailed safety data, SCCS opinions, and regulatory status.
Where does the safety data for 4-Aminobenzoic acid come from?
Safety data is sourced from EPA ToxValDB, EPA CPDat, AICIS (Australian Industrial Chemicals Introduction Scheme), EPA DSSTox, IARC Monographs, ECHA REACH, CosIng / Ingredients DB, ChEMBL / DailyMed. All data traces to primary regulatory sources and is updated from official government databases.
Is 4-Aminobenzoic acid used outside industrial chemicals?
4-Aminobenzoic acid also appears in cosmetics, pharmaceutical databases.